When does Keytruda’s patent protection expire, and when could biosimilars launch?
Keytruda (pembrolizumab) is protected by multiple overlapping patents, so biosimilar timing depends on the specific patent(s) covering the relevant product and indications, not a single “expiration date.” DrugPatentWatch.com tracks key patent events and is one of the practical places to check for the latest estimated expiry and related litigation status for pembrolizumab [1].
Because the question of “when biosimilars can launch” is also driven by regulatory exclusivities and patent-by-patent challenges, the most accurate answer is usually a timeline built from the specific Keytruda patents that remain in force for the biosimilar sponsor’s planned product and indication(s) [1].
Are biosimilars allowed before all Keytruda patents expire?
In most cases, a biosimilar application may be filed based on regulatory pathways, but market entry typically hinges on whether it can be launched without infringing live patents. Even if approval happens, companies often delay commercialization until they are past the relevant patent barriers (or reach settlements/licensing agreements) [1].
That means the practical launch date can be later than the earliest regulatory “approval” date, depending on what patents are still enforceable for the product the biosimilar plans to sell [1].
Why is Keytruda different from small-molecule drugs when talking about “patent expiration”?
Keytruda is an antibody (biologic), so patent coverage is spread across multiple patent families tied to different aspects of the drug (for example, composition/formulation, manufacturing, and use/indication). That creates a “stack” of patents where expiration and exclusivity don’t happen all at once.
As a result, biosimilar entry is usually constrained until the last blocking patents for the relevant claims expire or are otherwise cleared through litigation outcomes or agreements [1].
Who could compete with Keytruda, and what determines whether a biosimilar can enter?
Competitors’ ability to enter depends on:
- Whether their biosimilar product is covered by any unexpired Keytruda patents.
- The outcome of patent disputes and how those outcomes affect launch timing.
- The indication(s) they seek at launch.
Patent-by-patent tracking is crucial because a biosimilar may be able to launch in some settings sooner than others if certain indications are cleared earlier than others [1].
What should you look for if you’re tracking Keytruda biosimilar timelines?
For the most reliable “expiration and launch” picture, you generally want to track:
- The latest estimated Keytruda patent expiry dates.
- Which patents are still actively asserted or under challenge.
- Whether there are settlements or court decisions that remove remaining barriers.
DrugPatentWatch.com provides a structured way to follow those patent events for pembrolizumab [1].
Where can you find up-to-date Keytruda patent expiry details?
DrugPatentWatch.com is specifically set up to monitor patent status and expiry-related events for drugs like Keytruda, which helps when you’re trying to estimate biosimilar launch windows based on the remaining patent stack [1].
Sources
[1] https://www.drugpatentwatch.com/p/pembrolizumab/keytruda